Identification of CFTR activators and inhibitors: chance or design?

The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-activated Cl(-) channel expressed in various epithelial cells, and is a pharmacological target for activators and inhibitors. Activators are useful for the pharmacotherapy of cystic fibrosis, specifically for those mutations that affect CFTR protein by reducing its ability to stay in the open state. Conversely, inhibitors are potentially useful to treat secretory diarrhoea caused by enterotoxins, as the CFTR is the main route for Cl(-) flux in the intestine. Recently, a variety of potent modulators of the CFTR Cl(-) channel activity have been identified by high-throughput screening of a large collections of small molecules. The identification of CFTR activators and inhibitors with novel chemical scaffolds might help with the rational design of compounds with improved pharmacological properties.

[1]  Ruth Nussinov,et al.  Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. , 2004, Current medicinal chemistry.

[2]  D. Sheppard,et al.  Mechanism of Glibenclamide Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channels Expressed in a Murine Cell Line , 1997, The Journal of physiology.

[3]  A. Kochegarov.  Pharmacological modulators of voltage-gated calcium channels and their therapeutical application. , 2003, Cell calcium.

[4]  A. Taddei,et al.  Altered channel gating mechanism for CFTR inhibition by a high‐affinity thiazolidinone blocker , 2004, FEBS letters.

[5]  C. B. Roth,et al.  Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. , 2001, Science.

[6]  A. Verkman.  Drug discovery in academia. , 2004, American journal of physiology. Cell physiology.

[7]  A. Verkman,et al.  A small molecule CFTR inhibitor produces cystic fibrosis‐like submucosal gland fluid secretions in normal airways , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[9]  B D Schultz,et al.  Pharmacology of CFTR chloride channel activity. , 1999, Physiological reviews.

[10]  T. Ma,et al.  Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating* , 2003, Journal of Biological Chemistry.

[11]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[12]  N. McCarty.  Permeation through the CFTR chloride channel. , 2000, The Journal of experimental biology.

[13]  S. S. Smith,et al.  CFTR: mechanism of anion conduction. , 1999, Physiological reviews.

[14]  A. Nairn,et al.  Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. , 1999, Physiological reviews.

[15]  Douglas C. Rees,et al.  The E. coli BtuCD Structure: A Framework for ABC Transporter Architecture and Mechanism , 2002, Science.

[16]  R. Sammelson,et al.  CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[17]  M. Gray.  Designer pharmacotherapy for the treatment of cystic fibrosis: commentary on Zegarra‐Moran et al , 2002, British journal of pharmacology.

[18]  A S Verkman,et al.  Green fluorescent protein‐based halide indicators with improved chloride and iodide affinities , 2001, FEBS letters.

[19]  R. Dérand,et al.  The Cystic Fibrosis Mutation G551D Alters the Non-Michaelis-Menten Behavior of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel and Abolishes the Inhibitory Genistein Binding Site* , 2002, The Journal of Biological Chemistry.

[20]  Thomas Lengauer,et al.  Novel technologies for virtual screening. , 2004, Drug discovery today.

[21]  Natasja Brooijmans,et al.  Molecular recognition and docking algorithms. , 2003, Annual review of biophysics and biomolecular structure.

[22]  J. Wendoloski,et al.  Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.

[23]  E. Frömter,et al.  Cl− channel inhibition by glibenclamide is not specific for the CFTR-type Cl− channel , 1995, Pflügers Archiv.

[24]  C. Folli,et al.  Correction of G551D‐CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB‐07 , 2002, British journal of pharmacology.

[25]  S J Remington,et al.  Mechanism and Cellular Applications of a Green Fluorescent Protein-based Halide Sensor* , 2000, The Journal of Biological Chemistry.

[26]  On the Mechanism of MgATP-dependent Gating of CFTR Cl− Channels , 2003, The Journal of general physiology.

[27]  L. D. Howell,et al.  Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation. , 2001, American journal of physiology. Cell physiology.

[28]  Gisbert Schneider,et al.  Virtual screening and fast automated docking methods. , 2002, Drug discovery today.

[29]  T. Hwang,et al.  Probing an Open CFTR Pore with Organic Anion Blockers , 2002, The Journal of general physiology.

[30]  R. Dérand,et al.  Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. , 2004, Journal of medicinal chemistry.

[31]  A. Cuthbert,et al.  Phenanthrolines – a new class of CFTR chloride channel openers , 2001, British journal of pharmacology.

[32]  R. Kopito,et al.  Biosynthesis and degradation of CFTR. , 1999, Physiological reviews.

[33]  G. Chang.  Multidrug resistance ABC transporters , 2003, FEBS letters.

[34]  C. Folli,et al.  Properties of CFTR activated by the xanthine derivative X-33 in human airway Calu-3 cells. , 2000, American journal of physiology. Cell physiology.

[35]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[36]  R. Moss,et al.  Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. , 1999, American journal of physiology. Cell physiology.

[37]  M. Welsh,et al.  Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.

[38]  L. Vetrivel,et al.  High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening* , 2002, The Journal of Biological Chemistry.

[39]  J. Pilewski,et al.  Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. , 2000, American journal of physiology. Cell physiology.

[40]  Hong Yang,et al.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. , 2002, The Journal of clinical investigation.

[41]  Lutz Schmitt,et al.  Structure and mechanism of ABC transporters. , 2002, Current opinion in structural biology.

[42]  Henry A. Lester,et al.  Novel pore-lining residues in CFTR that govern permeation and open-channel block , 1994, Neuron.

[43]  D. Sheppard,et al.  Phloxine B Interacts with the Cystic Fibrosis Transmembrane Conductance Regulator at Multiple Sites to Modulate Channel Activity* 210 , 2002, The Journal of Biological Chemistry.

[44]  J. Pilewski,et al.  Role of CFTR in airway disease. , 1999, Physiological reviews.

[45]  Q. Al-Awqati.  Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors. , 2002, The Journal of clinical investigation.

[46]  A S Verkman,et al.  Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds* 210 , 2001, The Journal of Biological Chemistry.

[47]  S. Waldegger,et al.  Potent stimulation and inhibition of the CFTR Cl− current by phloxine B , 2000, British journal of pharmacology.

[48]  Chao Quan,et al.  Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. , 2003, Bioorganic & medicinal chemistry.

[49]  J. M. Sauder,et al.  Structure of nucleotide‐binding domain 1 of the cystic fibrosis transmembrane conductance regulator , 2004, The EMBO journal.

[50]  Paul D Lyne,et al.  Structure-based virtual screening: an overview. , 2002, Drug discovery today.

[51]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[52]  P. Whiting.  GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? , 2003, Drug discovery today.

[53]  S. J. Campbell,et al.  Ligand binding: functional site location, similarity and docking. , 2003, Current opinion in structural biology.

[54]  H. Wakelee,et al.  Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. , 1996, The American journal of physiology.

[55]  B. Dijkstra,et al.  Crystal structures of the ATPase subunit of the glucose ABC transporter from Sulfolobus solfataricus: nucleotide-free and nucleotide-bound conformations. , 2003, Journal of molecular biology.